EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Apontis Pharma AG's Enterprise Value is €79.04 Mil.
Apontis Pharma AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-10.12 Mil. Therefore, Apontis Pharma AG's EV-to-FCF for today is -7.81.
The historical rank and industry rank for Apontis Pharma AG's EV-to-FCF or its related term are showing as below:
XTER:APPH'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.72 Med: 4.43 Max: 291.8
Current: -7.72
During the past 6 years, the highest EV-to-FCF of Apontis Pharma AG was 291.80. The lowest was -7.72. And the median was 4.43.
XTER:APPH's EV-to-FCF is ranked worse than 100% of 547
companies
in the Drug Manufacturers industry
Industry Median: 23.07
vs XTER:APPH: -7.72
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Apontis Pharma AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Apontis Pharma AG's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's EV-to-FCF falls into.
Apontis Pharma AG's current Enterprise Value is €79.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apontis Pharma AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-10.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apontis Pharma AG (XTER:APPH) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Apontis Pharma AG's PE Ratio (TTM) for today is calculated as:
Apontis Pharma AG's share price for today is €11.35.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apontis Pharma AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.832.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Apontis Pharma AG EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Apontis Pharma AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTER:APPH has been successfully added to your 